Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach

Body Image

Volumn 5, Issue 1, 2008, Pages 13-27

  Phillips, Katharine A ^a   Hollander, Eric ^b  

^a BROWN UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Body dysmorphic disorder (BDD); Delusional disorder; Pharmacotherapy; Psychotropic medication; Treatment

Indexed keywords

BUSPIRONE; PIMOZIDE; SEROTONIN AGONIST; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BODY IMAGE; COGNITIVE THERAPY; DRUG ADMINISTRATION; DRUG COMBINATION; ELECTROCONVULSIVE THERAPY; HUMAN; METHODOLOGY; PSYCHOLOGICAL ASPECT; SOMATOFORM DISORDER; SUICIDE ATTEMPT;

BODY IMAGE; BUSPIRONE; COGNITIVE THERAPY; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ELECTROCONVULSIVE THERAPY; HUMANS; PIMOZIDE; SEROTONIN AGONISTS; SEROTONIN UPTAKE INHIBITORS; SOMATOFORM DISORDERS; SUICIDE, ATTEMPTED;

EID: 41549093182     PISSN: 17401445     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bodyim.2007.12.003     Document Type: Article

References (69)

1. Albertini R.S., and Phillips K.A. 33 cases of body dysmorphic disorder in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 38 (1999) 453-459
2. Albertini R.S., Phillips K.A., and Guvremont D. Body dysmorphic disorder in a young child (letter). Journal of the American Academy Child and Adolescent Psychiatry 35 (1996) 1425-1426
3. Allen A., Hadley S.J., Kaplan A., Simeon D., Friedberg J., Priday L., et al. An open-label trial of venlafaxine in body dysmorphic disorder. 6th International Obsessive Compulsive Disorder Conference Abstracts. Lanzarote, Spain (2003) p. 22
4. Bienvenu O.J., Samuels J.F., Riddle M.A., Hoehn-Saric R., Lang K.Y., Cullen B.A.M., et al. The relationship of obsessive compulsive disorder to possible spectrum disorders: Results from a family study. Biological Psychiatry 48 (2000) 287-293
5. Brady K.T., Austin L., and Lydiard R.B. Body dysmorphic disorder: The relationship to obsessive-compulsive disorder. Journal of Nervous and Mental Disorders 178 (1990) 538-540
6. Bridge J.A., Iyengar S., Salary C.B., Barbe R.P., Birmaher B., Pincus H.A., et al. Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: A meta-analysis of randomized controlled trials. Journal of the American Medical Association 15 (2007) 1683-1696
7. Carroll B.J. Response of major depression with psychosis and body dysmorphic disorder to ECT (letter). American Journal of Psychiatry 151 (1994) 288-289
8. Dyl J., Kittler J., Phillips K.A., and Hunt J.I. Body dysmorphic disorder and other clinically significant body image concerns in adolescent psychiatric inpatients: Prevalence and clinical characteristics. Child Psychiatry and Human Development 36 (2006) 369-382
9. Eisen J.L., Phillips K.A., Baer L., Beer D.A., Atala K.D., and Rasmussen S.A. The Brown Assessment of Beliefs Scale: reliability and validity. American Journal of Psychiatry 155 (1998) 102-108
10. Eisen J.L., Phillips K.A., Coles M., and Rasmussen S.A. Insight in obsessive compulsive disorder and body dysmorphic disorder. Comprehensive Psychiatry 45 (2004) 10-15
11. El-Khatib H.E., and Dickey T.O. Sertraline for body dysmorphic disorder (letter). Journal of the American Academy of Child and Adolescent Psychiatry 34 (1995) 1404-1405
12. Faravelli C., Salvatori S., Galassi F., Aiazzi L., Drei C., and Cabras P. Epidemiology of somatoform disorders: A community survey in Florence. Social Psychiatry and Psychiatric Epidemiology 32 (1997) 24-29
13. Gibbons R.D., Brown C.H., Hur K., Marcus S.M., Bhaumik D.K., Erkens J.A., et al. Early evidence on the effects of regulators' suicidality warnings on SSRI prescriptions and suicide in children and adults. American Journal of Psychiatry 164 (2007) 1356-1363
14. Gibbons R.D., Brown C.H., Hur K., Marcus S.M., Bhaumik D.K., and Mann J.J. Relationship between antidepressants and suicide attempts: an analysis of the Veterans Health Administration data sets. American Journal of Psychiatry 164 (2007) 1044-1049
15. Gibbons R.D., Hur K., Bhaumik D.K., and Mann J.J. The relationship between antidepressant prescription rates and rate of early adolescent suicide. American Journal of Psychiatry 163 (2006) 1898-1904
16. Grant J.E., Kim S.W., and Crow S.J. Prevalence and clinical features of body dysmorphic disorder in adolescent and adult psychiatric inpatients. Journal of Clinical Psychiatry 62 (2001) 517-522
17. Gunstad J., and Phillips K.A. Axis I comorbidity in body dysmorphic disorder. Comprehensive Psychiatry 44 (2003) 270-276
18. Hay G.G. Dysmorphophobia. British Journal of Psychiatry 116 (1970) 399-406
19. Heimann S.W. SSRI for body dysmorphic disorder (letter). Journal of the American Academy of Child and Adolescent Psychiatry 36 (1997) 868
20. Hollander E., Allen A., Kwon J., Aronowitz B., Schmeidler J., Wong C., et al. Clomipramine vs. desipramine crossover trial in body dysmorphic disorder: Selective efficacy of a serotonin reuptake inhibitor in imagined ugliness. Archives of General Psychiatry 56 (1999) 1033-1039
21. Hollander E., Cohen L.J., and Simeon D. Body dysmorphic disorder. Psychiatric Annals 23 (1993) 359-364
22. Hollander E., Cohen L., Simeon D., Rosen J., DeCaria C., and Stein D.J. Fluvoxamine treatment of body dysmorphic disorder (letter). Journal of Clinical Psychopharmacology 14 (1994) 75-77
23. Hollander E., Liebowitz M.R., Winchel R., Klumker A., and Klein D.F. Treatment of body dysmorphic disorder with serotonin reuptake blockers. American Journal of Psychiatry 146 (1989) 768-770
24. Jacobs B.L., van Praag H., and Gage F.H. Adult brain neurogenesis and psychiatry: A novel theory of depression. Molecular Psychiatry 5 (2000) 262-269
25. Jain S., Grant J.E., Menard W., Cerasoli S., and Phillips K.A. A chart-review study of SRI continuation treatment versus discontinuation in body dysmorphic disorder. Abstracts, National Institute of Mental Health NCDEU 44th Annual Meeting. Phoenix, AZ (2004) 231
26. McKay D., Neziroglu F., and Yaryura-Tobias J.A. Comparison of clinical characteristics in obsessive-compulsive disorder and body dysmorphic disorder. Journal of Anxiety Disorders 11 (1997) 447-454
27. Munro A., and Chmara J. Monosymptomatic hypochondriacal psychosis: A diagnostic checklist based on 50 cases of the disorder. Canadian Journal of Psychiatry 27 (1982) 374-376
28. National Collaborating Centre for Mental Health. Core interventions in the treatment of obsessive compulsive disorder and body dysmorphic disorder (A guideline from the National Institute for Health and Clinical Excellence, National Health Service) (2006), British Psychiatric Society and Royal College of Psychiatrists, London. http://www.nice.org.uk/page.aspx?o=289817
29. Neziroglu F., Stevens K.P., McKay D., and Yaryura-Tobias J.A. Predictive validity of the overvalued ideas scale: outcome in obsessive-compulsive and body dysmorphic disorders. Behavior Research and Therapy 39 (2001) 745-756
30. Otto M.W., Wilhelm S., Cohen L.S., and Harlow B.L. Prevalence of body dysmorphic disorder in a community sample of women. American Journal of Psychiatry 158 (2001) 2061-2063
31. Pallanti S., and Koran L.M. Intravenous, pulse-loaded clomipramine in body dysmorphic disorder: Two case reports. CNS Spectrums 1 (1996) 54-57
32. Perugi G., Giannotti D., Di Vaio S., Frare F., Saettoni M., and Cassano G.B. Fluvoxamine in the treatment of body dysmorphic disorder (dysmorphophobia). International Clinical Psychopharmacology 11 (1996) 247-254
33. Phillips K.A. Body dysmorphic disorder: The distress of imagined ugliness. American Journal of Psychiatry 148 (1991) 1138-1149
34. Phillips K.A. An open study of buspirone augmentation of serotonin-reuptake inhibitors in body dysmorphic disorder. Psychopharmacology Bulletin 32 (1996) 175-180
35. Phillips K.A. Pharmacologic treatment of body dysmorphic disorder. Psychopharmacology Bulletin 32 (1996) 597-605
36. Phillips K.A. Quality of life for patients with body dysmorphic disorder. Journal of Nervous and Mental Disease 188 (2000) 170-175
37. Phillips K.A. Psychosis in body dysmorphic disorder. Journal of Psychiatric Research 38 (2004) 63-72
38. Phillips K.A. The broken mirror: Understanding and treating body dysmorphic disorder. Revised and Expanded Edition (2005), Oxford University Press, New York
39. Phillips K.A. A placebo-controlled study of pimozide augmentation of fluoxetine in body dysmorphic disorder. American Journal of Psychiatry 162 (2005) 377-379
40. Phillips K.A. An open-label study of escitalopram in body dysmorphic disorder. International Clinical Psychopharmacology 21 (2006) 177-179
41. Phillips K.A., Albertini R.S., and Rasmussen S.A. A randomized placebo-controlled trial of fluoxetine in body dysmorphic disorder. Archives of General Psychiatry 59 (2002) 381-388
42. Phillips K.A., Albertini R.S., Siniscalchi J., Khan A., and Robinson M. Effectiveness of pharmacotherapy for body dysmorphic disorder: A chart-review study. Journal of Clinical Psychiatry 62 (2001) 721-727
43. Phillips K.A., Coles M.E., Menard W., Yen S., Fay C., and Weisberg R.B. Suicidal ideation and suicide attempts in body dysmorphic disorder. Journal of Clinical Psychiatry 66 (2005) 717-725
44. Phillips K.A., and Diaz S. Gender differences in body dysmorphic disorder. Journal of Nervous and Mental Disease 185 (1997) 570-577
45. Phillips K.A., Dwight M.M., and McElroy S.L. Efficacy and safety of fluvoxamine in body dysmorphic disorder. Journal of Clinical Psychiatry 59 (1998) 165-171
46. Phillips K.A., Hollander E., Rasmussen S.A., Aronowitz B.R., DeCaria C., and Goodman W.K. A severity rating scale for body dysmorphic disorder: Development, reliability, and validity of a modified version of the Yale-Brown Obsessive Compulsive Scale. Psychopharmacological Bulletin 33 (1997) 17-22
47. Phillips K.A., McElroy S.L., Dwight M.M., Eisen J.L., and Rasmussen S.A. Delusionality and response to open-label fluvoxamine in body dysmorphic disorder. Journal of Clinical Psychiatry 62 (2001) 87-91
48. Phillips K.A., McElroy S.L., Keck Jr. P.E., Pope Jr. H.G., and Hudson J.I. Body dysmorphic disorder: 30 cases of imagined ugliness. American Journal of Psychiatry 150 (1993) 302-308
49. Phillips K.A., McElroy S.L., Keck Jr. P.E., Pope Jr. H.G., and Hudson H.I. A comparison of delusional and nondelusional body dysmorphic disorder in 100 cases. Psychopharmacological Bulletin 30 (1994) 179-186
50. Phillips K.A., and Menard W. Suicidality in body dysmorphic disorder: A prospective study. American Journal of Psychiatry 163 (2006) 1280-1282
51. Phillips K.A., Menard W., Fay C., and Pagano M. Psychosocial functioning and quality of life in body dysmorphic disorder. Comprehensive Psychiatry 46 (2005) 254-260
52. Phillips K.A., Menard W., Fay C., and Weisberg R. Demographic characteristics, phenomenology, comorbidity, and family history in 200 individuals with body dysmorphic disorder. Psychosomatics 46 (2005) 317-332
53. Phillips K.A., Menard W., Pagano M., Fay C., and Stout R.L. Delusional versus nondelusional body dysmorphic disorder: Clinical features and course of illness. Journal of Psychiatric Research 40 (2006) 95-104
54. Phillips K.A., and Najjar F. An open-label study of citalopram in body dysmorphic disorder. Journal of Clinical Psychiatry 64 (2003) 715-720
55. Phillips K.A., Nierenberg A.A., Brendel G., and Fava M. Prevalence and clinical features of body dysmorphic disorder in atypical major depression. Journal of Nervous and Mental Disease 184 (1996) 125-129
56. Phillips K.A., Pagano M.E., and Menard W. Pharmacotherapy for body dysmorphic disorder: Treatment received and illness severity. Annals of Clinical Psychiatry 18 (2006) 251-257
57. Phillips K.A., Pinto A., Menard W., Eisen J.L., Mancebo M., and Rasmussen S.A. Obsessive-compulsive disorder versus body dysmorphic disorder: A comparison study of two possibly related disorders. Depression and Anxiety 24 (2007) 399-409
58. Phillips K.A., and Rasmussen S.A. Change in psychosocial functioning and quality of life of patients with body dysmorphic disorder treated with fluoxetine: a placebo-controlled study. Psychosomatics 45 (2004) 438-444
59. Phillips K.A., Siniscalchi J.M., and McElroy S.L. Depression, anxiety, anger, and somatic symptoms in patients with body dysmorphic disorder. Psychiatric Quarterly 75 (2004) 309-320
60. Pope Jr. H.G., Gruber A.J., Choi P., Olivardia R., and Phillips K.A. Muscle dysmorphia: An under recognized form of body dysmorphic disorder. Psychosomatics 38 (1997) 548-557
61. Rief W., Buhlmann U., Wilhelm S., Borkenhagen A., and Brahler E. The prevalence of body dysmorphic disorder: A population-based survey. Psychological Medicine 36 (2006) 877-885
62. Roose S.P., and Miyazaki M. Pharmacologic treatment of depression in patients with heart disease. Psychosomatic Medicine 67 (2005) S54-S57
63. Saxena S., Brody A., Maidment K.M., Dunkin J.J., Colgan M., Alborzian S., et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 21 (1999) 683-693
64. Simon G.E., and Savarino J. Suicide attempts among patients starting depression treatment with medications or psychotherapy. American Journal of Psychiatry 164 (2007) 1029-1034
65. Sondheimer A. Clomipramine treatment of delusional disorder, somatic type. Journal of the American Academy of Child and Adolescent Psychiatry 27 (1988) 188-192
66. Taylor C.B., Youngblood M.E., Catellier D., Veith R.C., Carney R.M., Burg M.M., et al. Effects of antidepressant mediation on morbidity and mortality in depressed patients after myocardial infarction. Archives of General Psychiatry 62 (2005) 792-798
67. Veale D., Boocock A., Gournay K., Dryden W., Shah F., Willson R., et al. Body dysmorphic disorder: A survey of fifty cases. British Journal of Psychiatry 169 (1996) 196-201
68. Williams J., Hadjistavropoulos T., and Sharpe D. A meta-analysis of psychological treatments for Body Dysmorphic Disorder. Behaviour Research and Therapy 44 (2006) 99-111
69. Zimmerman M., and Mattia J.I. Body dysmorphic disorder in psychiatric outpatients: Recognition, prevalence, comorbidity, demographic, and clinical correlates. Comprehensive Psychiatry 39 (1998) 265-270